Merit Medical Systems Inc. announced the U.S. commercial launch of the PreludeSync Evo radial compression device. The PreludeSync Evo is a sterile, single-use, disposable device used to assist in gaining hemostasis of the arterial percutaneous access site following catheterization procedures.

AtriCure Inc. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling claims for AtriClip left atrial appendage (LAA) management devices. These include changing the indication from occlusion of the LAA to exclusion, and also adding electrical isolation as a labeling claim.

Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy heart muscle tissue.

Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for below-the-knee (BTK) use of its MagicTouch drug-coated balloon catheter (DCB) for the treatment of peripheral artery disease (PAD). The company is now in a position to potentially disrupt this market and become a threat to larger manufacturers that have an established presence in the peripheral space, according to data and analytics company GlobalData.

Ultrasound imaging company Terason has partnered with DiA Imaging Analysis, provider of artificial intelligence (AI)-based solutions for ultrasound analysis, to provide its cardiac solutions on Terason's point-of-care ultrasound devices.

Patients with peripheral artery disease (PAD) were significantly less likely to face amputation after surgical intervention if they were on statin medications, according to a newly released report in the Journal for Vascular Surgery.1 Those patients also had fewer deaths over the 88-month review period.